Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen’s Aranesp Reimbursement Continues To Get Scrutiny From Capitol Hill

Executive Summary

The debate around Medicare reimbursement for Amgen's anemia treatments Aranesp and Epogen is being reopened by House Ways & Means Committee Chairman Bill Thomas (R-Calif.) as CMS drafts its annual payment update rule that addresses the issue

You may also be interested in...



Medicare’s Overdue Study On Changing EPO Payment Now Promised For 2007

A rapid change in Medicare policy on reimbursement for Amgen's Epogen (epoetin alfa) used in dialysis facilities is unlikely, despite impassioned criticism of the current policy from outgoing House Ways and Means Committee Chairman Bill Thomas (R-Calif.)

Medicare’s Overdue Study On Changing EPO Payment Now Promised For 2007

A rapid change in Medicare policy on reimbursement for Amgen's Epogen (epoetin alfa) used in dialysis facilities is unlikely, despite impassioned criticism of the current policy from outgoing House Ways and Means Committee Chairman Bill Thomas (R-Calif.)

Excessive EPO Use Will Be Examined In House Ways & Means Hearing

Representatives from the Government Accountability Office, CMS and FDA are expected to testify at a Dec. 6 House Ways & Means Committee hearing on controlling utilization of Amgen's EPO products Epogen and Aranesp in dialysis facilities

Related Content

UsernamePublicRestriction

Register

OM013202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel